← Eichor
Condition: Cisplatin Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cisplatin

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Affiliated Cancer Hospital & Institute of Guangzhou Medical · NCT04437329Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C
NA · 8 location(s) · Aichi Medical University · NCT07235007Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metasta
Phase 2 · 2 location(s) · Medical University of South Carolina · NCT07076212Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carbo
Phase 2 · 34 location(s) · National Cancer Institute (NCI) · NCT05198830A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179Neoadjuvant Therapy in Cervical Cancer
NA · 1 location(s) · Qilu Hospital of Shandong University · NCT06558682Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-r
Phase 1 · 1 location(s) · First Affiliated Hospital of Chongqing Medical University · NCT06916494Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06298968AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR
Phase 2 · 1 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06464068Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
Phase 2 · 5 location(s) · Centre Hospitalier Universitaire de Besancon · NCT04894370Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT06055738Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metas
Phase 2 · 1 location(s) · Fudan University · NCT06591650Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05394337Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Phase 2 · 9 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT04617756Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Phase 2/Phase 3 · 5 location(s) · InnoPharmax Inc. · NCT05065957BAI-BACE for Advanced Lung Squamous Cell Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06377735A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Out
Phase 2 · 58 location(s) · National Cancer Institute (NCI) · NCT06050252Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT06947668A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable I
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05967182Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07336147A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
Phase N/A · 1 location(s) · Turku University Hospital · NCT06551857Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Canc
Phase 3 · 33 location(s) · M.D. Anderson Cancer Center · NCT03583710Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade
Phase 2 · 1 location(s) · Myung-Ju Ahn · NCT05727410Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT03964753A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05182944TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Phase 3 · 1 location(s) · Beihua Kong · NCT02429700Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT02290145
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.